Opentrons Valuation, Funding & Investors

Opentrons is valued at $1.8B as of September 2021.

Last Opentrons valuation

$1.8B

Series C · Sep 2021

Last Opentrons funding round

$20M

Series D · Dec 2025

Cumulative funding Opentrons raised

$260M

across 6 funding rounds

Key investors in Opentrons

Opentrons Overview

About Opentrons

Opentrons is a Brooklyn-based manufacturer of open-source pipetting robots for life sciences labs. Its OT-2 system automates protocols like PCR setup and cell culture using Python scripting via Opentrons App. Launched in 2016, Opentrons supplies academic institutions and biotech firms worldwide, including partnerships with Harvard and AstraZeneca.


Founded

2014

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$1.8B (Sep 2021)

Opentrons Valuation

Opentrons is currently valued at $1.8B, based on its Series C in September 2021.

The $200M round was led by SoftBank Group, with participation from Jacket River and Khosla Ventures.

Opentrons valuation by funding round

Opentrons valuation by funding round
DateStageValuation
Sep 2021Series C$1.8B

Opentrons Funding History

Opentrons has raised a total of $260M across 6 funding rounds.

Opentrons' first fundraising round was a $7M seed round in March 2016. The most recent completed round was a $20M Series D in December 2025.

Opentrons funding rounds

Opentrons funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Dec 2025Series D-$20M-Opentrons Labworks, Inc. develops accessible lab automation robotics, including open-source liquid-handling robots like OT-2 and the next-generation Opentrons Flex, compatible with generative AI tools. The company accelerates innovation in research, biotechnology, and healthcare through its integrated lab platform, which includes business units Opentrons Robotics and Neochromosome. Founded in 2014 and headquartered in Long Island City, New York, Opentrons has raised over $200M historically, achieving unicorn status with earlier products. In December 2025, Opentrons announced a funding round raising $20.1M as an initial filing from a $56.6M offering, listed as Series C - II in some trackers. This follows prior rounds including a $200M Series C in September 2021 led by SoftBank Vision Fund and Khosla Ventures, valuing the company at $1.8B at that time, plus earlier seed, Series B, and other investments totaling around $241M to $270M across multiple rounds. Key investors include SoftBank Vision Fund, SOSV, Y Combinator, and Khosla Ventures. The company continues global expansion and R&D in robotic lab tools.
Sep 2021Series CSoftBank Group (lead); Jacket River; Khosla Ventures$200M$1.8BOpentrons Labworks Inc. develops an automated lab platform integrating robotics, assays, and operations to provide cost-effective solutions for life sciences and healthcare, including pipetting robots for drug discovery, genomics, proteomics, cell-based assays, and biochemical assays. The platform targets lab diagnostics and synthetic genomics markets with robotics and consumables as foundational components. On September 23, 2021, Opentrons announced a $200 million Series C funding round led by SoftBank Vision Fund 2, with participation from Khosla Ventures, bringing total funding raised to approximately $241 million across prior rounds including a $20.6 million Series B in 2020 and earlier seed investments from Y Combinator, SOSV, and others. The Series C round valued Opentrons at $1.8 billion post-money, as reported by multiple sources citing Bloomberg data. Proceeds are earmarked for scaling the platform globally, including development of new robotic tools, expansion of its biofoundry, creation of new diagnostic tests, and establishment of additional diagnostic labs to accelerate growth and commercialization. CEO Jon Brennan-Badal emphasized unlocking scientists' potential through affordable automation, while SoftBank's Angela Du highlighted the high value proposition in transformative healthcare and life sciences applications. This funding significantly outpaced prior raises, with the company's valuation jumping from $90 million the previous year. Opentrons plans to invest in vertically integrated, low-cost solutions to drive R&D, testing, and innovation. Key team additions were also announced to support platform scaling.
Aug 2020Series BSOSV (lead)$21M-Opentrons is a US-based developer of robotic technology for life science research, including automated pipetting robots used in drug discovery, genomics, proteomics, cell-based assays, and biochemical assays. The company, founded in 2013, participated in Y Combinator’s winter 2016 cohort and has received prior funding including a $10M seed round led by Khosla Ventures in 2018, $2.3M in November 2019, and $7.2M in 2017 from undisclosed investors. Existing backers include SOSV and Sands Capital. In August 2020, Opentrons raised $20.6M in a Series B round with SOSV as the lead investor, aimed at expanding market reach and enhancing product capabilities. This followed smaller rounds and built on the company's growth in laboratory automation. The company gained prominence during the Covid-19 pandemic by using its automated systems to reduce testing result times from 14 days to 24 hours and costs from $2,000 to $28, supporting a community of over 1,000 scientists in 46 countries. Later, in September 2021, Opentrons raised $200M in a Series C round led by SoftBank Vision Fund 2 with participation from Khosla Ventures, achieving a $1.8B valuation. Funds were allocated to developing new robotic tools, diagnostic tests, expanding its biofoundry, and global growth of its automated lab platform. Opentrons integrates lab robotics, assays, and operations for cost-effective solutions in lab diagnostics and synthetic genomics.
Nov 2019SeedMUUS$2M--
Mar 2018SeedKhosla Ventures (lead); Jeffrey B. Kindler; Lerer Hippeau; MBX Capital; Y Combinator; HAX; TGM ventures; Fifty Years; SOSV; SP Investment Fund$10M-Opentrons raised $10 million in a seed round in March 2018 led by Khosla Ventures, with participation from Y Combinator Continuity Fund, Lerer Hippeau Ventures, and former Pfizer CEO Jeff Kindler. The funding aimed to expand the product line, scale operations, and support development of OT-2 pipetting robots for biotech labs. Opentrons, founded in 2013 and a Y Combinator alum from 2016, builds affordable robots to automate routine lab tasks like pipetting for DNA sequencing and other experiments.
Mar 2016SeedY Combinator (lead); HAX; NYU Innovation Venture Fund; TSVC; SOSV$7M-Opentrons participated in Y Combinator's winter 2016 cohort and raised $7.2 million in a seed round in March 2016 led by Y Combinator, with investors including HAX, NYU Innovation Venture Fund, SOSV, and TSVC. The funding supported further development and marketing of initial pipetting robot products for life science research in drug discovery, genomics, and proteomics. Opentrons develops automated robotic technology for laboratory testing and assays. Subsequent rounds included a $10 million seed led by Khosla Ventures in 2018 with Y Combinator Continuity Fund, $20.6 million in August 2020 led by SOSV, and a $200 million Series C in September 2021 led by SoftBank Vision Fund 2 with Khosla Ventures at a $1.8 billion valuation. The Series C funded expansion of the automated lab platform, new robotic tools, diagnostic tests, and biofoundries.

Who has invested in Opentrons?

15 investors have backed Opentrons across its funding rounds, including SOSV, Y Combinator, Khosla Ventures, HAX, SoftBank Group and Lerer Hippeau.

Lead investors include SoftBank Group, SOSV, Khosla Ventures and Y Combinator.


Opentrons Investors

Investors in Opentrons by funding rounds participated
InvestorHQRoundsRoleFirst check
SOSVUnited StatesPrinceton, NJ3LeadMar 2016
Y CombinatorUnited StatesSan Francisco, CA2LeadMar 2016
HAXUnited StatesSan Francisco, CA2ParticipantMar 2016
Khosla VenturesUnited StatesSan Francisco, CA2LeadMar 2018
Jeffrey B. KindlerUnited StatesNew York City, NY1ParticipantMar 2018
Lerer HippeauUnited StatesNew York City, NY1ParticipantMar 2018
MBX CapitalUnited StatesNew York City, NY1ParticipantMar 2018
SoftBank GroupJapanTokyo1LeadSep 2021
TGM venturesUnited StatesLos Angeles, CA1ParticipantMar 2018
MUUSUnited StatesNew York City, NY1ParticipantNov 2019
Fifty YearsUnited StatesSan Francisco, CA1ParticipantMar 2018
Jacket RiverUnited StatesNew York City, NY1ParticipantSep 2021
NYU Innovation Venture FundUnited StatesNew York City, NY1ParticipantMar 2016

This data is available for Pro users. Sign up to see all 15 Opentrons investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Opentrons

Opentrons has acquired 1 company to date.

Last acquisition by Opentrons was on October 19th 2021. Opentrons acquired Zenith Ai for undisclosed valuation.


Latest Acquisitions by Opentrons

Zenith Ai
Description
Zenith AI is a biotechnology software company that develops Biostudio, a machine learning platform designed for life sciences researchers to train AI models on biological data. Headquartered in San Francisco, the platform supports drug discovery workflows by integrating datasets from genomics and proteomics. Zenith AI serves academic labs and biotech firms, enabling predictive modeling for protein structures and cellular pathways. Founded in 2023, it raised $5 million in seed funding from investors including Y Combinator. Biostudio processes terabytes of multimodal data daily, accelerating hypothesis testing in synthetic biology projects.
HQ CountryUnited Kingdom
HQ City
Belfast
Deal Date19 Oct 2021
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Opentrons acquisitions and their M&A valuation multiples.

Start Free Trial

Opentrons Competitors

Opentrons competitors include listed companies like Harbin Boshi Automation and Zen Technologies, and private ones like Sineva, Bedrock Robotics, Exotec and Geek+.

Public and private companies comparable to Opentrons
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SinevaChinaHefeiPrivate--$1.8B-
Bedrock RoboticsUnited StatesSan Francisco, CAPrivate--$1.8B-
Harbin Boshi AutomationChinaChinaPublicly listed$422M$106M$1.7B3.5x
ExotecFranceLillePrivate$100M-$2B20.0x
Geek+ChinaBeijingPrivate$150M-$2B13.3x
Zen TechnologiesIndiaIndiaPublicly listed$72M$27M$1.6B15.5x

Opentrons Public Comps

Opentrons is still privately-owned, but its public comps include Harbin Boshi Automation, Ennoconn, ATS, Allient, ROKAE Robotics, Googol Technology, Zen Technologies, Kardex Holding, Beijing Dahao Technology and AEM.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Harbin Boshi Automation$422M$106M3.5x3.5x14.0x11.4x
Ennoconn$4.5B$475M0.7x0.6x6.9x6.5x
ATS$2.1B$260M1.3x1.3x10.6x9.6x
Allient$554M$67M3.3x3.1x27.4x22.4x
ROKAE Robotics$78M($7M)20.7x-(221.3x)-
Googol Technology$82M$14M18.9x18.9x111.1x91.4x
Zen Technologies$72M$27M21.0x15.5x56.2x42.4x
Kardex Holding$979M$83M2.1x1.9x24.5x16.4x

This data is available for Pro users. Sign up to see all Opentrons competitors and their valuation data.

Start Free Trial

Common questions about Opentrons

When was Opentrons founded?Opentrons was founded in 2014.
Where is Opentrons headquartered?Opentrons is headquartered in New York City, NY, United States.
Is Opentrons publicly listed?No, Opentrons is a private, VC-backed company.
What is Opentrons' valuation?Opentrons was last valued at $1.8B in its Series C in September 2021.
How much funding has Opentrons raised?Opentrons has raised $260M across 6 funding rounds.
What was Opentrons' last funding round?Opentrons' last funding round was a $20M Series D in December 2025.
Who are Opentrons' investors?Opentrons' investors include SOSV, Y Combinator, HAX, Khosla Ventures, Jeffrey B. Kindler, Lerer Hippeau, MBX Capital, SoftBank Group, TGM ventures, MUUS and 5 others.
Which companies are comparable to Opentrons?Companies comparable to Opentrons include Sineva, Bedrock Robotics, Harbin Boshi Automation, Exotec, Geek+ and Zen Technologies.
How many companies has Opentrons acquired?Opentrons has acquired 1 company, including Zenith Ai.

See companies similar to Opentrons

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial